

Fax*Lilly*

Legal Department - Patent DivisionEli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285
U.S.A.

To: David Romeo, Ph.D., USPTO

Company: USPTO
Fax: 703-872-9306
Phone: 703-305-4050
Date: October 29, 2003

From: Caren D. Geppert
Fax: 317-276-5172
Phone: 317-651-4215
Total Pages: 4

Re:

Applicant : Edmonds Taylor Brian
Serial No. : 09/763,994
Filed : February 27, 2001
For : Human Latent Transforming Growth
Factor- β Binding Protein 3
Docket No. : X-12239

RECEIVED
CENTRAL FAX CENTER

OCT 29 2003

OFFICIAL**Privileged and Confidential Communication**

If there are any transmittal problems please call: (317) 651-2733.

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect), and return the original message to us at the above address via U.S. Postal Service.

Answers That Matter.

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

KELLY RAMSEY

Type or print name of person signing certification

Signature

Kelly Ramsey

Oct. 29, 2003

Date

**PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant	:	Edmonds Taylor Brian)	Conf. No:
Serial No.	:	09/763,994)	6826
Filed	:	February 27, 2001)	Group Art Unit:
For	:	Human Latent Transforming Growth Factor- β Binding Protein 3)	1647
Docket No.	:	X-12239)	Examiner
)	Romeo, David S.

RESPONSE TO RESTRICTION REQUIREMENT

OFFICIAL

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

**RECEIVED
CENTRAL FAX CENTER**

OCT 29 2003

Claims 32-45 are currently pending. The Examiner has made a restriction requirement under 35 U.S.C. §121. Applicant provisionally elects with traverse Group I and the species SEQ ID NO:2. Applicant respectfully requests, however, that all sequences specified in Claim 32, which is part of Group I, be examined together. The sequences are presented as a Markush group and are so linked as to form a single inventive concept. Restricting out members of this group is improper. In addition, Applicant respectfully requests that Group III, which encompasses a method of using the compounds of Group I, be examined with Group I.

With respect to Group I, the Examiner has indicated that the claims are directed to more than one species of the generic invention, and therefore, lack unity of invention.

Serial No. 09/763,994

Claim 32 encompasses an hLTBP-3 polypeptide which has at least 181 contiguous amino acids of a polypeptide selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6. These sequences all share the common structural feature of hLTBP-3 (SEQ ID NO:2). SEQ ID NO:4 is a fragment of hLTBP-3 (amino acids 1-188), and SEQ ID NO:6 represents a variant of hLTBP-3.

These polypeptides are claimed as a Markush group. Applicant respectfully asserts that it is not proper to restrict out members of a Markush group especially when the compounds included within the group share a common utility and a substantial structural feature. *See MPEP §803.02.*

In distinguishing restriction requirements made between different claims and those made in the context of a Markush group, the Federal Circuit noted that "it is never proper for an examiner to reject a Markush claim under 35 U.S.C §121. Section 121 simply does not authorize such a rejection." *In re Watkinson*, 900 F.2d 230, 232 (Fed. Cir. 1990). The MPEP §803.02 points out two specific cases where the Board of Appeals reversed an Examiner's decision to restrict out claims of a Markush group. *See In re Weber*, 580 F.2d 455 (C.C.P.A. 1978); *In re Haas*, 580 F.2d 461 (C.C.P.A. 1978). In *Weber*, the court stated that "an applicant has a right to have each claim examined on the merits" and noted that if a single claim is required to be divided up, that claim would never be considered on its merits. 580 F.2d at 458. The court held that while section 121 allows the restriction of independent and distinctive inventions, "[i]t does not...provide a basis for an examiner acting under the authority of the Commissioner to reject a particular claim on that basis." *Id.*


Thus, it is improper to restrict SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6 into three groups. This requirement would prevent Applicant from ever having the claim as filed considered on the merits. Applicant respectfully requests that this requirement for restriction be reconsidered.

The non-elected claims of Group III (claims 40 and 43) are drawn to a method for inhibiting or stimulating tissue growth comprising administering to a patient in need thereof a polypeptide of the present invention. According to MPEP §821.04, an Applicant is entitled to have non-elected claims drawn to a method of using a composition rejoined once composition of matter claims drawn to the same composition have been allowed. If the Examiner does not examine Group III along with the claims of Group I, Applicant will request rejoinder of the non-elected claims of Group III once Claims 32-36, and 38 have been found to be in condition for allowance.

Serial No. 09/763,994

The Applicant urges the Examiner to call the Applicant's attorney at (317) 651-4215 if a telephone conversation would be helpful in expediting prosecution of this case.

Respectfully submitted,



Caren D. Geppert
Attorney for Applicant
Registration No. 54,117
Phone: 317-651-4215

Eli Lilly and Company
Patent Division/CDG
P.O. Box 6288
Indianapolis, Indiana 46206-6288

RECEIVED
CENTRAL FAX CENTER

OCT 29 2003

October 29, 2003

OFFICIAL